Skip Navigation


Annals of Oncology Advance Access originally published online on October 16, 2006
Annals of Oncology 2007 18(2):394-395; doi:10.1093/annonc/mdl354
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/394    most recent
mdl354v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cardillo, A
Right arrow Articles by Colleoni, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cardillo, A
Right arrow Articles by Colleoni, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery

The first 10% of the full text of this article appears below.

Medical efforts and financial expenditures devoted to initial breast cancer staging represent a heavy burden on health care resources. Staging the disease accurately is considered to be important before surgery, in order to spare unnecessary treatment to patients with metastatic disease [1]. The role of 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography (FDG-PET) in the staging has . . . [Full Text of this Article]

A Cardillo1,*, C De Cicco2, G Paganelli2, R Ghisini1, G Peruzzotti1, A Balduzzi1, A Goldhirsch1, N Rotmensz3, P Veronesi4, A Luini4, M Intra4 and M Colleoni1

1 Research Unit in Medical Senology, Department of Medicine
2 Division of Nuclear Medicine
3 Unit of Quality Control
4 Division of Senology, European Institute of Oncology, Milan, Italy

* E-mail: anna.cardillo@ieo.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?